Chemistry:Cerdulatinib
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | PRT062070, PRT2070, DMVT-502 |
| Routes of administration | By mouth |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C20H27N7O3S |
| Molar mass | 445.54 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies.[1] It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK.[2]
It is being developed by Portola Pharmaceuticals; in September 2018 the FDA granted orphan drug status to cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL).[3]
See also
References
- ↑ "Syk inhibitors in clinical development for hematological malignancies". Journal of Hematology & Oncology 10 (1): 145. July 2017. doi:10.1186/s13045-017-0512-1. PMID 28754125.
- ↑ "The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer". The Journal of Pharmacology and Experimental Therapeutics 351 (3): 538–48. December 2014. doi:10.1124/jpet.114.218164. PMID 25253883.
- ↑ "Investors - News Release - Portola Pharmaceuticals, Inc." (in en). September 25, 2018. http://phx.corporate-ir.net/phoenix.zhtml?c=198136&p=irol-newsArticle&ID=2368929.
 |  |
